Akero Therapeutics Inc Stock
Akero Therapeutics Inc Stock
Currently there is a rather positive sentiment for Akero Therapeutics Inc with 5 Buy predictions and 2 Sell predictions.
With a target price of 61 € there is a positive potential of 29.87% for Akero Therapeutics Inc compared to the current price of 46.97 €.
Our community identified positive and negative aspects for Akero Therapeutics Inc stock for the coming years. 2 users see the criterium "Revenue growth" as a plus for the Akero Therapeutics Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Akero Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akero Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 1.880% | 12.739% | 1.659% | -50.864% | -28.501% | -67.883% | -94.618% |
| Evolus Inc | -0.520% | 7.961% | -10.945% | -55.318% | -29.083% | -48.467% | -57.056% |
| Sangamo Therapeutics Inc. | -1.540% | 1.388% | -29.790% | -61.259% | -33.162% | -84.467% | -97.559% |
Comments
Akero Therapeutics (NASDAQ:AKRO) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Show more
Ratings data for AKRO provided by MarketBeat